Zogenix, Inc. (“Zogenix”),
a private, specialty pharmaceutical company, today announced that it has
filed a registration statement with the Securities and Exchange
Commission ("SEC") relating to the proposed initial public offering of
shares of its common stock. The number of shares to be offered and the
price range for the offering have not yet been determined. The shares of
common stock to be sold in this offering are proposed to be sold by
Zogenix, Inc.
Banc of America Securities LLC is the sole book-running manager for the
offering. Leerink Swann, Thomas Weisel Partners LLC and Susquehanna
Financial Group, LLLP are co-lead managers. This offering will be made
only by means of a prospectus. Once available, a copy of the preliminary
prospectus for this offering may be obtained from Banc of America
Securities LLC, Capital Markets (Prospectus Fulfillment) by e-mail to dg.prospectus_distribution@bofasecurities.com
or by mail to Banc of America Securities LLC, Capital Markets
Operations, 100 West 33rd Street, 3rd Floor, New York, NY 10001.
A registration statement relating to these securities has been filed
with the SEC, but has not yet become effective. These securities may not
be sold nor may offers to buy be accepted prior to the time the
registration statement becomes effective. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy nor
shall there be any sale of these securities in any state in which such
offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state.
About Zogenix
Zogenix, Inc., with offices in Emeryville and San Diego, CA, is a
private, specialty pharmaceutical company with two proprietary product
candidates in late-stage development for the treatment of central
nervous system disorders and pain. The company's lead product candidate, sumatriptan
DosePro™ (previously Intraject®),
enables needle-free subcutaneous delivery of sumatriptan for the
treatment of acute migraine and cluster headache. Zogenix submitted a
New Drug Application with the U.S. Food and Drug Administration for sumatriptan
DosePro in December 2007, and it was accepted for filing by the FDA in
March 2008. Zogenix’s second product
candidate, ZX002, is a novel controlled release formulation of hydrocodone
for the treatment of chronic pain. This product candidate has completed
Phase 2 clinical trials, and the company anticipates initiating the
Phase 3 clinical program in the second half of 2008. The company also
plans to license the patented DosePro drug delivery system to other
companies. For additional information, visit www.zogenix.com.
|